Question or request:

Does the Medical Advisory Team recommend that providers in New Mexico administer the Pfizer-BioNTech COVID-19 vaccine to persons 12 years of age and older?

Recommendations:

The Medical Advisory Team (MAT) Vaccine Safety and Efficacy Workgroup has reviewed the relevant documents related to the Pfizer-BioNTech COVID-19 vaccine as provided by the manufacturer, the U.S. Food and Drug Administration, and the U.S. Centers for Disease Control and Prevention and concurs with the conclusions that the vaccine may prevent serious or life-threatening disease and that the known and potential benefits of the product outweigh the known and potential risks of the product. Therefore, the MAT recommends:

1. For those individuals who elect to receive a vaccine, approved healthcare providers in New Mexico should administer the Pfizer-BioNTech COVID-19 vaccine consistent with the Emergency Use Authorization issued by the U.S. Food and Drug Administration and the clinical guidance provided by the U.S. Centers for Disease Control and Prevention.

2. Approved healthcare providers in New Mexico who administer the Pfizer-BioNTech COVID-19 vaccine should ensure that each potential vaccine recipient or their legal guardian receives the required vaccine information sheet to allow for a well-informed decision and receives the required vaccination documentation card upon vaccination.

3. Approved healthcare providers who administer the Pfizer-BioNTech COVID-19 vaccine to children should ensure that appropriate parent or legal guardian consent has been obtained according to the applicable laws of the State of New Mexico.

4. Approved healthcare providers and health systems should monitor on-going and updated guidance from U.S. Food and Drug Administration and the U.S. Centers for Disease Control and Prevention related to the management of vaccine supplies, which may be provided on official websites or via official email messages to pharmacies, professional associations, or state officials.

Assessment:

1. There are several types of vaccines against COVID-19 being developed, each using different technology and immunological principles. Some types represent established methods of vaccine production, while others use new technology for which there is limited precedent. The Regulatory Affairs Professionals Society has provided a website that summarizes COVID-19 vaccine technology and regulatory status. ¹

2. The U.S. Food and Drug Administration (FDA) is responsible for the certification and licensure of new vaccines, following review of data and reports generated by clinical trials. Vaccines licensed in the United States must meet statutory and regulatory requirements for vaccine development and approval, including for quality, development, manufacture, and control. Prior to licensure, and under extraordinary conditions such as the COVID-19 pandemic, the FDA may issue an Emergency Use Authorization (EUA) for a vaccine that has been sufficiently studied in well-controlled clinical trials, making it reasonable to believe that it may prevent serious or life-threatening disease and that the known and potential benefits of the product outweigh the known and potential risks of the product.
3. Following the issuance of an EUA, the U.S. Centers for Disease Control and Prevention Advisory Committee on Immunization Practices (CDC ACIP) develops recommendation on how to use the vaccine to control disease, and then forwards those recommendations for approval and publication by the CDC Director and the U.S. Department of Health and Human Services.

4. All vaccines against COVID-19 being considered for use in New Mexico will have undergone study in controlled clinical trials with ongoing safety monitoring. These clinical trials will have undergone several phases, with interim results published and reviewed by the scientific community and the FDA. Full descriptions of the clinical trials and their results are available to the public through a repository website of the National Library of Medicine. On-going FDA safety and effectiveness monitoring will occur for all vaccines given EUA and for vaccines that receive full FDA approval.

5. As of May 10, 2021 the FDA updated the Emergency Use Authorization for the Pfizer-BioNTech COVID-19 vaccine to include children from 12 to 15 years old, and CDC ACIP has approved its use in people 12 years of age and older.

6. A fact sheet and information to guide vaccine administration has been provided by the FDA for the Pfizer-BioNTech COVID-19 vaccine.

7. A patient information fact sheet (FAQ) for the Pfizer-BioNTech COVID-19 vaccine has been developed by the FDA and its distribution to each potential vaccine patient will be required prior to administration.

8. Additional clinical guidelines for providers have been developed by the CDC that further describe vaccine procedures and post-vaccination observation, special populations considerations, vaccine and booster dose timing, vaccination after COVID-19 infection, testing after vaccination, co-administration with other vaccines, and other clinical considerations, and that assist in differentiating post-vaccine local and systemic reactions from symptoms of COVID-19.

Additional considerations:

Vaccine administration, particularly for special populations, should occur via shared decision-making between the provider and recipient using informational materials provided by the FDA and CDC in order to allow for a well-informed decision based on the risks and benefits of the vaccine.

Updates to FDA and CDC guidance for the second dose of the Pfizer-BioNTech COVID-19 vaccine include a recommended dosing interval of 3 weeks. If it is not feasible to adhere to the recommended interval, the second dose may be administered up to 6 weeks (42 days) after the first dose.

Providers administering the vaccine should carefully review the recommendations for offering vaccine to members of special populations as defined in the CDC clinical considerations, and be aware of exclusion of individuals under the age of 12 years.

Providers should be aware that the use of the Pfizer-BioNTech COVID-19 vaccine is contraindicated for individuals with prior severe allergic reactions or anaphylactic reactions to injectable therapy or any vaccine. The CDC has provided guidance for the management of anaphylaxis at sites providing vaccination.

The clinical trial results for children between the ages of 12 and 15 showed a different distribution and occurrence of vaccine adverse reactions (such as pain at the injection site, fatigue, fever, and headache) in children versus adults, with some reactions occurring with greater frequency in children. Adverse reactions were not considered to outweigh the benefits of the vaccine for any age group.
Contributors:

Justin Baca, MD, PhD, UNM Health Sciences Center, Department of Emergency Medicine
Laura Banks, DVM, MPH, UNM Health Sciences Center, Department of Emergency Medicine
Steven B Bradfute, PhD, UNM Department of Internal Medicine, Center for Global Health
Meghan Brett, MD, UNM Department of Internal Medicine, Division of Infectious Diseases
Bryce Chackerian, PhD, UNM Molecular Genetics and Microbiology
Sara Del Valle, PhD, Los Alamos National Laboratory, Information Systems and Modeling
Andrea Demeter, MD, Presbyterian Healthcare Services
Jon Femling, MD, PhD, UNM Health Sciences Center, Department of Emergency Medicine
Kathryn A. Hanley, PhD, NMSU Department of Biology
Bette Korber, PhD, Los Alamos National Laboratory, Theoretical Biology and Biophysics
David Peabody, PhD, UNM Molecular Genetics and Microbiology

Resources/References:

3. Clinical Trials.gov: https://clinicaltrials.gov/
4. FDA EUA Letter: https://www.fda.gov/media/144412/download
5. FDA Provider Fact Sheet and Prescribing Information: https://www.fda.gov/media/144413/download
6. FDA Patient Fact Sheet: https://www.fda.gov/media/144414/download
7. CDC Clinical Guidance: https://www.cdc.gov/vaccines/covid-19/info-by-manufacturer/pfizer/clinical-considerations.html
10. CDC Interim considerations for the management of anaphylaxis: https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/anaphylaxis-management.html